Back to Search
ARTHUR KAVANAUGH, M.D.
M.D.
Rheumatology Physician
NPI: 1679584486IndividualAccepts Medicare
Education
ST. LOUIS COLLEGE OF PHYSICIANS AND SURGEONS
Class of 1984
Research & Publications (20)
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
PMID 19333944·Arthritis Rheum·2009
3-trial
Infection prophylaxis in antirheumatic therapy: emphasis on vaccination.
PMID 19444117·Curr Opin Rheumatol·2009
6-review
Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.
PMID 17644541·Ann Rheum Dis·2008
3-trial
Economic consequences of established rheumatoid arthritis and its treatment.
PMID 17870036·Best Pract Res Clin Rheumatol·2007
6-review
Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials.
PMID 17708740·Bull NYU Hosp Jt Dis·2007
6-review
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
PMID 17114188·Ann Rheum Dis·2007
3-trial
Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
PMID 16932716·Nat Clin Pract Rheumatol·2006
6-review
Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.
PMID 16763453·Curr Opin Rheumatol·2006
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 9350 CAMPUS POINT DR, MAIL CODE 0997
LA JOLLA, CA 92037 - Phone
- (858) 657-7044
Quick Facts
- NPI
- 1679584486
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 42
- Publications
- 20
Are you this provider?
Claim Your Profile